BR9907912A - Composition, processes to treat cancer, to elicit T lymphocytes that infiltrate a mammalian tumor, to elicit a delayed hypersensitivity response to a mammalian tumor, and to prepare hapten-modified tumor cell membranes, and, isolated membrane of mammalian tumor cell - Google Patents
Composition, processes to treat cancer, to elicit T lymphocytes that infiltrate a mammalian tumor, to elicit a delayed hypersensitivity response to a mammalian tumor, and to prepare hapten-modified tumor cell membranes, and, isolated membrane of mammalian tumor cellInfo
- Publication number
- BR9907912A BR9907912A BR9907912-7A BR9907912A BR9907912A BR 9907912 A BR9907912 A BR 9907912A BR 9907912 A BR9907912 A BR 9907912A BR 9907912 A BR9907912 A BR 9907912A
- Authority
- BR
- Brazil
- Prior art keywords
- tumor cell
- elicit
- tumor
- processes
- mammalian
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 11
- 239000012528 membrane Substances 0.000 title abstract 11
- 210000004881 tumor cell Anatomy 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 230000005951 type IV hypersensitivity Effects 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO, PROCESSOS PARA TRATAR CâNCER, E PARA PREPARAR UMA MEMBRANA DE CéLULAS TUMORAIS MODIFICADA COM HAPTENO, MEMBRANA ISOLADA DE CéLULA TUMORAL DE ANIMAL DOMéSTICO, E, PROCESSOS PARA ELICITAR LINFóCITOS T QUE SE INFILTRAM EM UM TUMOR DE UM MAMìFERO, PARA ELICITAR UMA RESPOSTA IMUNE INFLAMATóRIA A UM TUMOR DE UM MAMìFERO, E PARA ELICITAR UMA RESPOSTA A HIPERSENSIBILIDADE DO TIPO ATRASADA A UM TUMOR DE UM MAMìFERO". A presente invenção é direcionada a membranas de células tumorais isoladas, suas composições, processos de produzir as membranas e composições, e processos de tratamento de câncer. As composições da presente invenção incluem uma composição preparada de uma célula tumoral que é modificada por hapteno. As membranas de células tumorais e as composições da invenção têm as propriedades, quando administradas a um mamífero que esteja sofrendo de um tumor maligno do mesmo tipo da dita célula tumoral, de eliciar os linfócitos T que se infiltram no tumor do mamífero e de eliciar uma resposta imune inflamatória contra o tumor do mamífero, e de eliciar uma resposta de hipersensibilidade do tipo retardado ao tumor do mamífero. As membranas e composições da invenção também estimulam as células T in vitro. Os processos da presente invenção são direcionados ao tratamento do câncer, compreendendo administrar uma quantidade terapeuticamente eficaz de uma membranas de células tumorais. A presente invenção é também direcionada a um processo de produzir uma membranas de células tumorais modificada por hapteno e a formas de dosagem contendo as membranas."COMPOSITION, PROCESSES TO TREAT CANCER, AND TO PREPARE A HAPPENE-MODIFIED TUMOR CELL MEMBRANE, DOMESTIC ANIMAL TUMOR CELL ISOLATED MEMBRANE, AND PROCESSES TO ELICITATE T LYMPHOCYTES THAT INFILITATE AN EMPHASIS OF A TYPE LYMPHIC NUMBER IN ONE HUMAN RESUME. INFLAMMATORY IMMUNE TO A MAMMALIAN TUMOR, AND TO ELICIT A TYPE HYPERSENSITIVITY RESPONSE DELAYED TO A MAMMALIAN TUMOR ". The present invention is directed to isolated tumor cell membranes, their compositions, processes for producing the membranes and compositions, and cancer treatment processes. The compositions of the present invention include a composition prepared from a tumor cell that is modified by hapten. Tumor cell membranes and compositions of the invention have the properties, when administered to a mammal suffering from a malignant tumor of the same type as said tumor cell, to elicit T lymphocytes that infiltrate the mammalian tumor and to elicit a inflammatory immune response against the mammalian tumor, and to elicit a delayed type hypersensitivity response to the mammalian tumor. The membranes and compositions of the invention also stimulate T cells in vitro. The processes of the present invention are directed towards the treatment of cancer, comprising administering a therapeutically effective amount of a tumor cell membrane. The present invention is also directed to a process of producing a hapten modified tumor cell membranes and to dosage forms containing the membranes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2501298A | 1998-02-17 | 1998-02-17 | |
| PCT/US1999/003536 WO1999040925A2 (en) | 1998-02-17 | 1999-02-17 | Hapten-modified tumor cell membranes and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9907912A true BR9907912A (en) | 2000-10-24 |
Family
ID=21823570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9907912-7A BR9907912A (en) | 1998-02-17 | 1999-02-17 | Composition, processes to treat cancer, to elicit T lymphocytes that infiltrate a mammalian tumor, to elicit a delayed hypersensitivity response to a mammalian tumor, and to prepare hapten-modified tumor cell membranes, and, isolated membrane of mammalian tumor cell |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1054690A2 (en) |
| JP (1) | JP2002502880A (en) |
| KR (1) | KR20010041018A (en) |
| CN (1) | CN1291105A (en) |
| AR (1) | AR015237A1 (en) |
| AU (1) | AU2686999A (en) |
| BR (1) | BR9907912A (en) |
| CA (1) | CA2320969A1 (en) |
| IL (1) | IL137791A0 (en) |
| PL (1) | PL342856A1 (en) |
| WO (1) | WO1999040925A2 (en) |
| ZA (1) | ZA991245B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1067960A2 (en) * | 1998-04-09 | 2001-01-17 | Thomas Jefferson University | A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| US6248585B1 (en) | 1998-11-19 | 2001-06-19 | Thomas Jefferson University | Compositions for preserving haptenized tumor cells for use in vaccines |
| JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
| US7297330B2 (en) | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| US7612251B2 (en) | 2000-09-26 | 2009-11-03 | Pioneer Hi-Bred International, Inc. | Nucleotide sequences mediating male fertility and method of using same |
| CA2489076A1 (en) | 2002-06-10 | 2003-12-18 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| WO2017189281A1 (en) * | 2016-04-27 | 2017-11-02 | The Regents Of The University Of Michigan | C3d cellular and acellular vaccines for the prevention and treatment of cancer |
| CN115137814A (en) * | 2022-07-01 | 2022-10-04 | 可蓝赛生物医药(上海)有限公司 | Tumor vaccine adjuvant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086134A (en) * | 1973-09-18 | 1978-04-25 | University Of Glasgow | Method for preparation of vaccine against feline leukemia |
| AU727316B2 (en) * | 1995-06-07 | 2000-12-07 | Thomas Jefferson University | Hapten modified tumor cell extract and methods of treating or screening for cancer |
-
1999
- 1999-02-17 IL IL13779199A patent/IL137791A0/en unknown
- 1999-02-17 AU AU26869/99A patent/AU2686999A/en not_active Abandoned
- 1999-02-17 PL PL99342856A patent/PL342856A1/en not_active Application Discontinuation
- 1999-02-17 WO PCT/US1999/003536 patent/WO1999040925A2/en not_active Application Discontinuation
- 1999-02-17 BR BR9907912-7A patent/BR9907912A/en not_active Application Discontinuation
- 1999-02-17 ZA ZA9901245A patent/ZA991245B/en unknown
- 1999-02-17 EP EP99907137A patent/EP1054690A2/en not_active Withdrawn
- 1999-02-17 JP JP2000531176A patent/JP2002502880A/en not_active Withdrawn
- 1999-02-17 CN CN99803065A patent/CN1291105A/en active Pending
- 1999-02-17 KR KR1020007009049A patent/KR20010041018A/en not_active Application Discontinuation
- 1999-02-17 CA CA002320969A patent/CA2320969A1/en not_active Abandoned
- 1999-02-23 AR ARP990100710A patent/AR015237A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1054690A2 (en) | 2000-11-29 |
| JP2002502880A (en) | 2002-01-29 |
| KR20010041018A (en) | 2001-05-15 |
| WO1999040925A2 (en) | 1999-08-19 |
| WO1999040925A3 (en) | 1999-10-21 |
| CN1291105A (en) | 2001-04-11 |
| CA2320969A1 (en) | 1999-08-19 |
| PL342856A1 (en) | 2001-07-16 |
| ZA991245B (en) | 1999-08-18 |
| AU2686999A (en) | 1999-08-30 |
| AR015237A1 (en) | 2001-04-18 |
| IL137791A0 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9307104A (en) | Reinforcing preparations of host and migrant defense mechanisms with single peak water-soluble b-glycan methods to produce a reinforcing preparation of host defense meanisms to prevent infection in a mammal to stimulate wound repair and healing and to stimulate the proliferation of platelets pharmaceutical composition and method for treating infection in mammals | |
| CN109431873B (en) | Composition for repairing and relieving skin inflammation | |
| Xia et al. | Nutritional and medicinal value | |
| BR9910187A (en) | Process and composition for inducing an anti-tumor response in a mammalian patient suffering from a tumor | |
| Kim et al. | Beneficial effects on skin health using polysaccharides from red ginseng by‐product | |
| Mandal-Ghosh et al. | Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against breast tumor associated antigen | |
| BR9907912A (en) | Composition, processes to treat cancer, to elicit T lymphocytes that infiltrate a mammalian tumor, to elicit a delayed hypersensitivity response to a mammalian tumor, and to prepare hapten-modified tumor cell membranes, and, isolated membrane of mammalian tumor cell | |
| Zhou et al. | β-Nicotinamide mononucleotide (NMN) administrated by intraperitoneal injection mediates protection against UVB-induced skin damage in mice | |
| Ekambaram et al. | Hydrolysable tannin-rich fraction from Terminalia chebula Retz. fruits ameliorates collagen-induced arthritis in BALB/c mice | |
| Durant et al. | Calcium and A23187-induced cytolysis of mouse thymocytes | |
| BR0015597A (en) | Use of antibodies as vaccines | |
| CN103892269A (en) | Black medlar sun-screening and whitening tablet | |
| AU2013380577B2 (en) | Camelid compound(s), composition(s) and method(s) | |
| JPS6219525A (en) | Production of plant-originated bioactive substance and composition containing said substance | |
| WO2011039629A2 (en) | Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer | |
| CA2773277A1 (en) | Colostrum composition | |
| KR102289551B1 (en) | A skin-care agent containing hyaluronic acid complex | |
| Dos Santos et al. | Effects of Cordyceps sinensis on macrophage function in high-fat diet fed rats and its anti-proliferative effects on IMR-32 human neuroblastoma cells. | |
| CN107737032B (en) | Medicinal skin care product for chapped skin | |
| EP3568131B1 (en) | Composition comprising 7-hydroxymatairesinol for use in the treatment and in the prevention of trichological diseases of inflammatory and/or hormonal origin | |
| Guo et al. | Alleviation of ultraviolet‐B radiation‐induced photoaging using saussurea medusa maxim polysaccharide | |
| IT1271688B (en) | HYBRID MOLECULES FOR ANTI-CANCER TREATMENT THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | |
| Pielok et al. | Betulin–application in dermatology and cosmetology | |
| BR9815983A (en) | Processes for treating selected cancer from the group consisting of adencarcinoma and leukemia, to elicit t-lymphocytes to infiltrate a human tumor, to elicit an inflammatory immune response to a human tumor, to elicit a delayed type hypersensitivity response to a tumor of a human, and, composition for the treatment of cancer | |
| Aaronson et al. | Inhibition by soluble ribonucleic acid of stimulatory effect of liver template ribonucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |